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ABSTRACT 
Aim: The aim of this study was to review our experience with gestations in autoimmune hepatitis patients. 
Background: There are only limited data describing pregnancy in patients with autoimmune hepatitis.  
Patients and methods: Retrospective analysis of pregnancies with autoimmune hepatitis followed in Centro Hospitalar 
do Porto, Portugal in the last ten years.  
Results: We reported nine pregnancies in seven patients with autoimmune hepatitis. Two patients had documented liver 
cirrhosis prior to the pregnancy. In this study, 66.7% of patients were treated with azathioprine and 88.9% with prednisolone. 
Clinical improvements were observed in 11.1% of pregnancies and 22.2% exacerbations were diagnosed. There were six live 
births and two preterm deliveries (preterm delivery rate of 33%). We also report three first trimester miscarriages (early 
gestation miscarriage rate of 33%).  There were no neonatal or maternal deaths.  
Conclusion: The favorable obstetric outcome is a realistic expectation in patients with autoimmune hepatitis. Tight 
monitoring and control of asymptomatic and unpredictable exacerbations, which are unrelated to the severity of the 
underlying disease, are essential to the prognosis of the current pregnancy.   
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Introduction  
  1Autoimmune hepatitis (AIH) is an autoimmune 
liver disorder described in 1953 (1). This pathology 
is characterized by a progressive hepatocellular 
inflammation that cannot be explained by alcohol 
consumption, viral infection, exposure to 
hepatotoxic drugs, or genetic liver disorders (2-5). 
AIH usually affects young women at childbearing 
age (2). In spite of the frequently associated 
oligomenorrhea (6), the number of pregnancies 
described in these patients are becoming more 
common as a result of the better clinical 
management (3). Optimal management during 
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pregnancy is not yet well defined (7), and flares 
occur in 7 to 33% of pregnancies (7-11) and 11 to 
86% postpartum (7-11). The majority of these 
flares can be controlled with an increment of 
immunosuppression (7-11). However, severe flares 
with hepatic decompensation have been described 
(10).  
Pregnancy in these patients is associated with a 
higher than normal rate of miscarriage, stillbirth, 
and premature delivery (5,7-13). In the presence of 
portal hypertension with oesophageal varices, the 
risk of bleeding is higher during pregnancy, 
particularly in the second half of gestation (14). 
Fetal outcomes in pregnancies with AIH are good 
and similar to other autoimmune disorders (10) 
with live birth rates being superior to 70% in the 
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recent series (7-11). The aim of this study was to 
review our experience with gestations in AIH 
patients.  
 
Patients and Methods 
We conducted a retrospective descriptive study 
that included all pregnant patients with a diagnosis 
of AIH that were followed in the Obstetric 
Department of Centro Hospitalar do Porto, 
Oporto, Portugal, between 2004 and 2014. Seven 
patients with a total of nine pregnancies were 
followed. The course of gestation, delivery and 
puerperium were analyzed retrospectively, and 
data was collected from patients’ medical records. 
The diagnosis of AIH was established by our 
Internal Medicine/Hepatology department based 
on IAHG criteria (15). Cirrhotic patients were 
identified according to the presence of previous 
histologic findings. 
All patients were followed by a 
multidisciplinary team, constituted by 
hepathologists and high-risk obstetricians. 
Antenatal visits were scheduled once a month up to 
28 weeks of pregnancy, every two weeks up to 32 
weeks, and thereafter weekly. A pre-conceptional 
liver function evaluation was performed in all cases 
and periodic hepatic evaluation was performed with 
monthly analytical evaluation. In patients with 
hepatic cirrhosis and portal hypertension, 
oesophageal varices evaluation was performed 
during the second trimester and prophylactic 
treatment applied when indicated. The type and 
dose of immunosuppressant drugs were noted. Fetal 
ultrasound evaluation was routinely performed in 
all pregnancies in all trimesters. 
Maternal and obstetric complications during 
gestation and puerperium were registered. Adverse 
pregnancy outcome was defined as miscarriage 
(fetal loss before the 20th week of gestation), 
preterm delivery (delivery before the 37th week of 
gestation), and development of hypertensive 
disorders of pregnancy or perinatal death (stillbirth 
or neonatal death).  
An exacerbation of AIH was defined as a 
twofold increase in serum transaminases or 
appearance of symptoms. Disease remission was 
defined as an analytic improvement with 
normalization of serum transaminases levels (16). 
Caesarean delivery was performed for 
obstetrical indications only, except in the presence 
of cirrhosis.  
 
Results 
Patient characteristics 
Seven patients with nine pregnancies were 
included. Mean age at conception was 31.3 years 
(23-43 years) and the average time between 
diagnosis and pregnancy was 8.2 years (2-19 
years). All patients had a previous hepatic biopsy 
to confirm the diagnosis. Two patients had 
histologically proven cirrhosis before pregnancy. 
One patient had an overlap syndrome with 
primary biliary cirrhosis. Before pregnancy, eight 
women were treated with prednisolone (88.9%) 
and six (66.7%) with azathioprine. The detailed 
profile is shown in table 1.  
Disease activity during pregnancy 
Two patients (22,2%) experienced a flare 
during pregnancy. One patient showed elevation 
of hepatic enzymes during the first trimester 
before a miscarriage. This analytic alteration 
resolved spontaneously after the pregnancy loss. 
Another patient experienced a flare at the end of 
the second trimester, at the 27th week of gestation 
(table 1 - patient B, pregnancy 4). This flare up 
was resistant to the increment of medication 
(increment of prednisolone dosage to 1mg/Kg/day 
plus azathioprine 100mg/day). No other causes for 
the analytical exacerbation were found. This 
allowed the diagnosis of a resistant AIH flare.  
Termination of pregnancy by caesarean section 
was performed to control hepatic disease at the 
33th week of pregnancy. One patient experienced 
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an analytical improvement after the second 
trimester (table 1 – patient G, pregnancy 9).  The 
disease remained stable in other pregnancies. 
There were no clinical or analytical exacerbations 
during puerperium. 
 
 
Table 1. Pregnancies with autoimmune hepatitis 
Patient Pregnancy Age Obstetric 
History 
Maternal disease Medication prior 
pregnancy 
Medication during 
pregnancy 
Pregnancy 
evolution 
Newborn Post-
pregnancy 
evolution 
A 1 25 Gravida 2 
Para 1+0 
AIH type 1 
diagnosed in 2000 
(4 years before 
pregnancy) 
Liver cirrhosis 
(Child-Pugh A) 
Azathioprine 
50mg 2id 
Prednisolone 5mg /day 
Azathioprine 
50mg 2id 
Prednisolone 
40mg/day 
Acetylsalicylic acid 
(ASA) 100mg/day 
Ø 
complications 
Spontaneous labour 
Vaginal delivery 
36 weeks 
2800g Apgar Index 9/10 
1st minute/5th minute 
Ø 
complications 
B 2 25 Gravida 1 
Para 0 
AIH type 1 
diagnosed in 2000 
(9 years before 
pregnancy) 
Thalassemia 
Minor 
 
Azathioprine 50mg 
2id 
Prednisolone 
7,5mg/day 
  
 
 
Azathioprine 50mg 
2id 
Prednisolone 
7,5mg/day 
  
 
First trimester 
miscarriage 
- Ø 
complications 
3 28 Gravida 2 
Para 0+1 
AIH type 1 
diagnosed in 2000 
(10 year before 
pregnancy) 
Thalassemia 
Minor 
Prednisolone 
7,5mg/day 
  
Prednisolone 
7,5mg/day 
ASA 100mg/day 
First trimester 
miscarriage 
- Ø 
complications 
4 29 Gravida 3 
Para 0+2 
AIH type 1 
diagnosed in 2000 
(10 year before 
pregnancy) 
Thalassemia 
Minor 
Positivity for 
antiphospholipid 
antibodies) 
Prednisolone 
7,5mg/day 
Hydroxychloroquine 
400mg/day 
 
 
Prednisolone 
7,5mg/day (dose 
increment at the end of 
second trimester up to 
60 mg/day) 
Hydroxychloroquine 
400mg/day 
Enoxaparin 40mg/day 
Azathioprine 50mg 
2x/day (beginning at 
27th week) 
Acetylsalicylic acid 
100mg/day 
 
Analytical and 
clinical 
exacerbation, 
beginning at 
27th week of 
pregnancy 
Elective caesarean at form 
maternal reason 33th 
week of pregnancy 
1950g 
Apgar Index 8/9 1st 
minute/5th minute 
Good clinical 
and analytical 
evolution 
during the first 
weeks 
postpartum 
C 5 43 Gravida 4 
Para3+0 
AIH type 1 
diagnosed in 
2007(2 year 
before pregnancy) 
Prednisolone 
7,5mg/day 
Ursodeoxycholic acid 
250mg 3id 
Prednisolone 
7,5mg/day 
Ursodeoxycholic acid 
250mg 3id 
Ø 
complications 
Urgent caesarean at 38th 
week of pregnancy, 
secondary to foetal 
distress (true umbilical 
knot) 
3065g Apgar Index 2/7 1st 
minute/5th minute 
Ø 
complications 
D 6 27 Gravida 1 
Para 0 
AIH type 1 
diagnosed in 1992 
(19 year before 
pregnancy) 
Liver cirrhosis 
with portal 
hypertension 
(Child-Pugh A) 
Azathioprine 50mg 
2id 
Propranolol 40mg 
3xid 
Prednisolone 
7,5mg/day 
 
Azathioprine 50mg 
2id 
Propranolol 40mg 
3xid 
Prednisolone 
7,5mg/day 
 
Ø 
complications 
Urgent caesarean at 38th 
week of pregnancy, 
secondary to fetal distress 
after spontaneous 
membrane rupture  
2550g Apgar Index 7/8 1st 
minute/5th minute 
Ø 
complications 
E 7 34 Gravida 1 
Para 0 
AIH type 3 
diagnosed in 2001 
(12 year before 
pregnancy) 
 
Azathioprine 50mg 
2id 
Prednisolone 5mg/day 
 
Azathioprine 50mg 
2id 
Prednisolone 5mg/day 
 
First trimester 
miscarriage 
Analytical 
exacerbation 
2 weeks before 
miscarriage 
- Good clinical 
and analytical 
evolution 
during the first 
weeks after 
miscarriage 
F 8 38 Gravida 5 
Para 3+1 
AIH type 1 
diagnosed in 2009 
(3 years before 
pregnancy) 
 
Azathioprine 50mg 
2id 
 
Azathioprine 50mg 
2id 
 
Ø 
complications 
Elective caesarean at 38th 
week of pregnancy, pelvic 
presentation  
3618g /Apgar Index 
8/9 1st minute/5th minute 
Ø 
complications 
G 9 33 Gravida 1 
Para 0 
AIH type 1 
diagnosed in 2009 
(5 years before 
pregnancy) 
Azathioprine 50mg 
2id 
Prednisolone 5mg/day 
Azathioprine 50mg 
2id 
Prednisolone 5mg/day 
Analytical 
improvement 
during the 
second 
trimester 
Vaginal delivery 
3750g /Apgar Index 
9/10 1st minute/5th minute 
Ø 
complications 
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Obstetrical outcome 
All patients started obstetric evaluation before 
the 10th week of pregnancy. There were three first 
trimester miscarriages (33.3% of pregnancies). 
One patient experienced two first trimester 
miscarriages, and in the subsequent study of this 
obstetric complication, a positive result of anti-
phospholipid antibodies was found. The third 
pregnancy of this patient was medicated with 
acetylsalicylic acid (ASA) 100mg/day and 
enoxaparin 40mg/d. This patient experienced a 
clinical aggravation as previously described. 
There were no other obstetric complications 
like hypertensive disorders of pregnancy, foetal 
growth restriction, stillbirths, foetal malformations 
or neonatal deaths. We report a caesarean rate of 
67% (see table 1 for indications).  
 
Discussion 
Autoimmune hepatitis is a rare cause of chronic 
hepatic disease in Portugal (17). Therefore, the 
association between AIH and pregnancy is rare in 
our country. 
We report a high rate of first trimester 
miscarriage (33.3%), which was also described 
previously by Candia, et al. (18), Schramm, et al. (9) 
and Terrabuio et al (7). In our study, two 
miscarriages occurred in the same patient, and 
during the investigation of recurrent abortions, a 
positive title for antiphospholipid antibodies was 
found. The association between antiphospholipid 
antibodies and AIH is not frequently found, 
especially during pregnancy (19). This patient 
achieved a viable pregnancy under treatment for 
antiphospholipid antibodies syndrome.  
We also report a preterm delivery rate of 33.3% 
with one case being iatrogenic, secondary to a severe 
hepatic flare, and one case spontaneous. There were 
no hypertensive disorders of pregnancy, maternal 
deaths or hepatic failure in our group of patients.   
A high rate of caesarean delivery was found in 
this group of patients. The way of delivery should be 
chosen by obstetric indication. However, some 
authors consider that the rise in the abdominal 
pressure in the presence of hepatic cirrhosis, increase 
portal hypertension and the risk of bleeding. In our 
group of patients, caesarean sections were all made 
for obstetric indications. 
We report 2 cases of hepatic flare during 
pregnancy (22.2%). However, unlike the previous 
reports, we didn’t find any exacerbation during the 
postpartum period (7-11). In our institution, we 
usually increase the corticosteroid dosage during the 
postpartum to reduce the probability of a flare, as 
supported by the same author (20), which could 
explain the absence of AIH flares during the 
postpartum period. One flare was controlled after a 
first-trimester miscarriage without increment of 
medication dosage, and the second case was 
refractory to the corticosteroid increment of dosage. 
Therefore, the pregnancy was interrupted at the 33rd 
week of gestation. The usage of azathioprine during 
pregnancy has been considered secure (21-24), and 
all our kept this drug during pregnancy. No cases of 
foetal malformations were detected in this group of 
patients.  
The good obstetric outcome could be expected in 
patients with AIH. However, a tight surveillance by 
a trained multidisciplinary team is mandatory to 
allow early diagnose and treatment of AIH flares, 
reducing the ominous complications described in the 
first series of pregnancies in these patients. 
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